Bristol-Meyers (NYSE:BMY) said it agreed to acquire ZymoGenetics (NASDAQ:ZGEN) for $9.75 per share, in a deal valued at 885 million A Bloomberg report said Vodafone (NYSE:VOD) will sell it...
Recently ZymoGenetics, Inc. (NASDAQ:ZGEN) announced the commencement of the second part of a mid-stage study (EMERGE) involving its PEG-Interferon lambda (formerly known as IL-29) and ribavirin in tre...
Following the release of the disappointing third quarter fiscal 2010 results on May 4, 2010, most of the analysts covering Myriad Genetics, Inc. (NASDAQ:MYGN) have made downward revisions to their 201...
Myriad Genetics Inc.’s (NASDAQ:MYGN) third quarter fiscal 2010 earnings of $0.33 per share fell short of the Zacks Consensus Estimate by $0.05. The company had earned $0.38 per share in the year...
Myriad Genetics Inc.’s (NASDAQ:MYGN) third quarter fiscal 2010 earnings of 33 cents per share fell short of the Zacks Consensus Estimate by 5 cents. The company earned 38 cents per share (from conti...
Chemical manufacturer EI DuPont de Nemours & Company (NYSE:DD) is spending $40 million on plant genetics busine...
ZymoGenetics, Inc. (ZGEN) reported fourth quarter earnings of 19 cents per share, which was above the Zacks Consensus Estimate by a penny. The company had suffered a loss of 13 cents in the year-ago q...
ZymoGenetics, Inc. (ZGEN) reported fourth quarter earnings of 19 cents per share, which was above the Zacks Consensus Estimate by a penny. The company had suffered a loss of 13 cents in the year-ago q...
Myriad Genetics Inc. (MYGN) reported second quarter fiscal 2010 earnings of 36 cents per share, two cents above the Zacks Consensus Estimate. The company had earned 22 cents in the year-ago period. Th...
ZymoGenetics Inc. (ZGEN) recently announced that it will sell 12 million shares of its common stock in a public offering. The underwriters will have a 30-day option to purchase up to a further 1.8 mil...